Medical Affairs | Deciphera

Recent News

November 5, 2026

Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial

November 5, 2026

Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial

October 26, 2026

Expert Video Summary: Results of an Exploratory ctDNA Biomarker Analysis in Advanced GIST

October 26, 2026

IGNITE: A Phase III Study of Tirabrutinib Versus Rituximab and Temozolomide Combination Therapy in Relapsed/Refractory Primary Central Nervous System Lymphoma

October 26, 2026

Vimseltinib for Patients With Tenosynovial Giant Cell Tumor: A Multicenter, Open-Label, Phase 2 Trial

Resources

Grant Funding

Through grants, sponsorships and research opportunities, Deciphera is committed to our patients, caregivers, advocacy groups, healthcare providers (HCPs) and researchers. Learn More.

Expanded Access Policy

Deciphera may be able to provide access to an investigational medicine, under certain limited conditions through our Expanded Access Program (EAP). Learn More.